%0 Journal Article
%T Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
%A Aaron H. Burstein
%A Brendon Binneman
%A Carol Cronenberger
%A Catherine Sattler
%A Clare B. Billing
%A Jr.
%A Clifford R. Jack
%A Jr.
%A Jae-Hong Lee
%A Kejal Kantarci
%A Ken Sprenger
%A Martin M. Bednar
%A Pamela F. Schwartz
%A Qinying Zhao
%A Scot Styren
%A Sharon Cohen
%A William T. Duggan
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2017
%R 10.1016/j.trci.2017.04.003
%X Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD)
%K Alzheimer's disease
%K Amyloid ¦Â
%K Biomarkers
%K Cerebrospinal fluid
%K Immunotherapy
%K Monoclonal antibody
%K Pharmacokinetics
%K Pharmacodynamics
%K Phase-II study
%K Ponezumab
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651443/